Locoregional Therapy for XXXX with and without Extrahepatic Spread.

@entity1 @entity5 @entity409 @entity6687 @entity157 @entity1349
PURPOSE: To evaluate the use of locoregional therapy in @entity1 with @entity157 ( @entity157 ) with and without @entity6687 ( @entity6687 ). MATERIALS AND METHODS: @entity1 who underwent locoregional therapy for @entity157 were identified from institutional databases. Clinicopathologic and treatment characteristics were compared between @entity1 with and without @entity6687 . Survival and progression were assessed using the Kaplan-Meier method, and multivariate analysis was completed. RESULTS: Of 224 @entity1 , 39 (17%) had radiologic evidence of @entity6687 . @entity1 without @entity6687 were older than @entity1 with @entity6687 (68.8 y    10.1 vs 65.0 y    11.7, P = .04); underlying @entity409 characteristics were not different. Type of locoregional therapy (hepatic artery embolization vs drug-eluting bead transarterial chemoembolization, P = .12; radiofrequency ablation + embolization, P = .07) was similar. Progression occurred in 75% (169/224) of @entity1 . Progression-free survival (PFS) did not differ between the 2 groups (13 [10.3-15.7] mo @entity6687 vs18 [14.6-21.4] mo no @entity6687 , P = .13). @entity1349 ( @entity1349 ) was 13 (4.1-21.9) months and 25 (20.4-29.6) months in the @entity6687 and no @entity6687 groups, respectively (P = .02). On multivariate analysis, systemic therapy after locoregional treatment was the only variable independently associated with PFS (hazard ratio [HR] 0.70 [0.49-1.00], P = .04); @entity6687 (HR 1.60 [1.02-2.50], P = .04) and @entity5 size (HR 1.77 [1.21-2.58], P = .003) were independently associated with worse @entity1349 . CONCLUSIONS: @entity1 with @entity157 and limited @entity6687 treated with locoregional therapy had worse @entity1349 than @entity1 without @entity6687 ; PFS was not different. Use of systemic therapy after locoregional therapy was independently associated with improved PFS in this cohort. Further prospective studies of locoregional, systemic, and combination therapies are necessary to improve outcome in these high-risk @entity1 .
